Abstract
Adequate management of patients with chronic obstructive pulmonary disease (COPD) is not getting less relevant year by year. Sustainable management of the patient requires additional tools and methods as well as approaches to evaluating the effectiveness of treatment schemes. It is known that the ability of drugs to improve functional parameters does not always lead to an improvement in patients’ well-being or enhance their daily living. In this regard, it is especially important to evaluate the quality of life as a marker of treatment efficacy. The aim of the study was to evaluate the effect of vaccination on the quality of life in patients with COPD during a 3-year follow up. Material and Methods: 362 male patients diagnosed with COPD were included in the study. 13-valent conjugate pneumococcal vaccine Prevenar-13 (PCV13) and polyvalent Pnevmo23 pneumococcal vaccine (PPV23) were used in vaccination. The quality of life (QoL) evaluation was done using two questionnaires, the Russian version of the St. George Hospital Respiratory Questionnaire (SGRQ) and the universal COPD assessment test (CAT). Results and conclusions: vaccination with PCV13 and PPV23 had a positive impact on the quality of life in the first year after vaccination, but the effect of PPV23 decreased in the third year of follow-up. Quality of life questionnaires allow to focus on the right treatment strategy both in early and long-term follow up of patients with COPD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have